Latest Hotspot

Vasa Therapeutics Initiates Phase 1 Trial of VS-041 for Heart Failure Treatment

6 September 2024
3 min read

Vasa Therapeutics ("Vasa"), a clinical-stage biopharmaceutical company focused on innovative treatments for cardiovascular and metabolic aging, announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted clinical trial authorization (CTA) to Vasa. This authorization allows Vasa to begin a Phase 1 first-in-human clinical trial aimed at assessing the safety, tolerability, and pharmacokinetics of its experimental drug VS-041 in healthy adult volunteers. VS-041 is an oral medication with a unique mechanism of action, potentially for treating heart failure with preserved ejection fraction (HFpEF).

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

"The MHRA's approval represents a significant advancement in our goal to develop VS-041 as a disease-modifying therapy for HFpEF," stated Artur Plonowski, MD, PhD, CEO of Vasa Therapeutics. "Presently, no HFpEF treatments are available that enhance the structural characteristics of the myocardium or offer lasting clinical benefits. By inhibiting endotrophin release, a biomarker and mediator of fibrotic and inflammatory responses, VS-041 could become the first personalized treatment strategy for HFpEF, particularly for patients with elevated endotrophin levels and a high risk of poor outcomes."

The start of the Phase 1 trial for VS-041 coincides with the extension of the Company's seed funding, increasing the total to $11 million. The funding was spearheaded by Orphinic Scientific SA with contributions from i&i Biotech Fund I SCSp. The funds will be utilized to support the clinical development of VS-041 and further Vasa’s preclinical initiatives.

VS-041 is an orally administered compound identified and developed by Vasa for the prospective treatment of HFpEF. In preclinical HFpEF models, VS-041 significantly reduces cardiac fibrosis and improves diastolic heart function. The compound also suppresses the secretion of endotrophin from primary human cardiac fibroblasts. In GLP toxicology studies, VS-041 showcased an excellent safety and tolerability profile. The preclinical development of VS-041 received co-funding from the European Regional Development Fund and the Polish National Centre for Research and Development (POIR.01.01.01-00-1210/19-01).

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of September 5, 2024, there are 68 investigational drugs for the collagen targets, including 94 indications, 86 R&D institutions involved, with related clinical trials reaching 241, and as many as 167692 patents.

The drug VS-041 is a small molecule drug developed by Vasa Therapeutics, Inc. It targets collagen and is intended for the treatment of cardiovascular diseases, with a specific focus on heart failure with normal ejection fraction. As of the latest available information, the drug is in the preclinical phase, indicating that it is still undergoing laboratory and animal testing to assess its safety and efficacy.

图形用户界面, 文本, 应用程序

描述已自动生成

GC Biopharma and Hanmi Pharmaceutical get U.S. FDA IND approval for Phase 1/2 trial
Latest Hotspot
3 min read
GC Biopharma and Hanmi Pharmaceutical get U.S. FDA IND approval for Phase 1/2 trial
6 September 2024
GC Biopharma revealed that its joint effort with Hanmi Pharmaceutical on the Fabry treatment 'LA-GLA' (GC1134A/HM15421) has been granted IND approval by the U.S. FDA to initiate a Phase 1/2 clinical study.
Read →
REGENXBIO Reports Positive Results for RGX-121, Showing Lasting Systemic Impact
Latest Hotspot
4 min read
REGENXBIO Reports Positive Results for RGX-121, Showing Lasting Systemic Impact
6 September 2024
REGENXBIO Inc. revealed encouraging findings from the Phase I/II/III CAMPSIITE® study of RGX-121, aimed at treating Mucopolysaccharidosis Type II (MPS II).
Read →
LENZ Therapeutics Submits NDA to FDA for Novel Eye Drop Treatment for Presbyopia
Hot Spotlight
2 min read
LENZ Therapeutics Submits NDA to FDA for Novel Eye Drop Treatment for Presbyopia
5 September 2024
LENZ Therapeutics, a biopharmaceutical company dedicated to developing the first and only eye drop based on aceclidine (LNZ100) to improve near vision in presbyopia patients.
Read →
Evommune Begins Phase 2 Study of Oral MRGPRX2 Antagonist EVO756 in Chronic Inducible Urticaria
Latest Hotspot
3 min read
Evommune Begins Phase 2 Study of Oral MRGPRX2 Antagonist EVO756 in Chronic Inducible Urticaria
5 September 2024
Evommune has announced the initiation of a Phase 2 trial for EVO756, with the first patient now enrolled.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.